Alterity Therap Limited (ATH)
20mins delayed
Movement
1 Year Return
Alterity Therap Limited Chart
| Share price | |
| Last | |
| Change | |
| Volume | |
| Turnover | |
| Market Cap | $37.88 million |
| Today's Movement | |
| Prev. Close | |
| Open | |
| Day Range | - |
| VWAP | |
| Historical Stats | |
| 52w Range | - |
| 4w Avg Volume | |
| 4w Avg Turnover | |
| (delayed) | |
ATH Statistics
18 April
1,126 / 2,323
ASX Size Rank
1yr Return
vs Sector (1yr)
-9.45%
vs ASX 200 (1yr)
-4.47%
$37.88 million
Market Cap
Share Issue
860.84 million
All Ords (%)
N/A
Short Sold
0%
Current Fundamentals
18 April
N/A
PE Ratio
EPS ($)
-0.019
Earnings Yield
-42.27%
NTA ($)
2.03
N/A
Dividend Yield
DPS ($)
-
Gross Div. Yield
-
Gross DPS ($)
-
Company Overview
Alterity Therapeutics Limited (ATH, formerly Prana Biotechnology Limited) is an Australian biotechnology company with a focus on the development of pharmaceutical products designed to treat the underlying causes of degeneration of the brain and the eye as the aging process progresses Potential applications for ATH's MPAC (Metal-Protein Attenuating Compound) technology including Alzheimer's, Parkinson's and Huntington's diseases and brain cancer.
Former Names
Prana Biotechnology Ltd (PBT), 11/04/2019
Upcoming Calendar
| 30 Aug 2019 | Report (Prelim) |
| 30 Aug 2019 | Report (Annual) |
| 27 Feb 2020 | Report (Interim) |
Dividend History
| Ex-Date | Amount | Franking | Type | Payable |
|---|---|---|---|---|
| No dividends paid in the last 5 years | ||||
See Upcoming Dividends for all ASX companies.
Announcements
| Date | Heading | Pages | File Size | Time |
|---|---|---|---|---|
Broker Consensus
The buy, hold and sell recommendations from Australian stockbroking firms are combined to form a "broker consensus". See the Consensus Data posts for more information.
ATH is not covered by a major broker.
Directors & Management
| Name | Title | Since | Bio |
|---|---|---|---|
| Mr David Sinclair | Non-Executive Director | Apr 2019 |
|
| Mr Geoffrey Paul Kempler | Executive Director, Chief Executive Officer, Executive Chairman | Nov 1997 |
|
| Mr Brian Derek Meltzer | Non-Executive Director | Dec 1999 |
|
| Mr Peter Marks | Non-Executive Director | Jul 2005 |
|
| Mr Lawrence Gozlan | Non-Executive Director | Aug 2011 |
|
| Mr Tristan Edwards | Non-Executive Director | Apr 2019 |
|
| Kathryn Andrews | Chief Financial Officer | N/A | |
| David Stamler | Chief Medical Officer and Senior Vice President Clinical Development | N/A | |
| Phillip Hains | Company Secretary | N/A |
Director Transactions
ATH directors must report any change in shareholding to the ASX within 5 business days.
See Director Transactions for all ASX companies.
| Date | Director | Type | Amount | Price | Value | Notes |
|---|---|---|---|---|---|---|
| 16/11/18 | Ira Shoulson | Issued | 1,250,000 | $0.044 | $55,000 | Issue of options. |
Shareholder Distribution
| Holding Size | 1 - 1,000 | 1,001 - 5,000 | 5,001 - 10,000 | 10,001 - 100,000 | 100,001 and over | Total Shareholders |
|---|---|---|---|---|---|---|
| No. of Shareholders | 515 | 973 | 458 | 851 | 189 | 2,986 |
Top 20 Shareholders
| Name | Shares | Capital |
|---|---|---|
| HSBC Custody Nominees (Australia) Limited | 389,889,040 | 72.61% |
| Jagen Pty Ltd | 15,567,983 | 2.90% |
| Baywick Pty Ltd |
14,165,000 | 2.64% |
| Merrill Lynch (Australia) Nominees Pty Limited | 6,006,707 | 1.12% |
| P Morgan Nominees Australia Limited | 5,867,548 | 1.09% |
| Mr James V Babcock | 3,980,263 | 0.74% |
| Nrb Developments Pty Ltd | 2,970,000 | 0.55% |
| Citos Super Pty Ltd |
2,656,714 | 0.49% |
| Moubray Pty Ltd |
2,000,000 | 0.37% |
| Robert & Ardis James Foundation/C | 1,826,024 | 0.34% |
| Neurotransmission Pty Ltd | 1,672,433 | 0.31% |
| Citicorp Nominees Pty Limited | 1,562,830 | 0.29% |
| Kempler Super Pty Ltd |
1,492,212 | 0.28% |
| Mr Johnny Boris Martinovich | 1,220,122 | 0.23% |
| Carlingwood Pty Ltd |
1,213,099 | 0.23% |
| Ms Jia Lu | 1,149,164 | 0.21% |
| Dacoma Holdings Pty Limited |
1,125,000 | 0.21% |
| Mr Lukasz Pieprzyk | 1,056,227 | 0.20% |
| One Lucky Oak Pty Ltd |
1,040,432 | 0.19% |
| Mr Nicholas Joseph Boekel | 1,000,000 | 0.19% |
| All other shareholders | 14.81 % | |
The Top 20 Shareholders of ATH hold 85.19% of shares on issue.
ATH Share Price History
| Date | Close | Change | % Change | Open | High | Low | Volume | Turnover |
|---|---|---|---|---|---|---|---|---|
ATH Historical Data
Download up to 20 years of share price history.
| Year | Closing Price (30 June) | Last Trade |
|---|
Offical data as published by ASX. See more Data Downloads.
Company Details
Principal Activity: Commercialise research into Parkinsonian movement disorders, Alzheimer's disease, Huntington disease and other neurodegenerative disorders.
Incorporated: in VIC on 11/11/1997 as Prana Corporation Pty Ltd. Incorporation status changed to "Limited" on 26/11/1999. Name changed to Prana Biotechnology Limited on 05/01/2000.
Level 3, 460 Bourke St
Melbourne VIC 3000
All data on this page is supplied by the ASX, Morningstar and Market Index. Read the disclaimer.